Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

87.5%

+0.9% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

14%

1 of 7 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

5(62.5%)

Phase 1

2(25.0%)

Phase 3

1(12.5%)

8Total

Phase 2(5)

Phase 1(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT03081481Phase 2Completed

Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer

Role: lead

NCT00889707Phase 2Completed

Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic Hyperplasia

Role: lead

NCT00379561Phase 1Completed

PSA-Activated PSA-PAH1 for Locally Recurrent Prostate Cancer

Role: lead

NCT01966614Phase 3Completed

Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH

Role: lead

NCT02499848Phase 2Completed

Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer

Role: lead

NCT01454349Phase 1Completed

Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)

Role: lead

NCT00797940Phase 2Withdrawn

Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1)

Role: lead

NCT00686088Phase 2Completed

An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy

Role: lead

All 8 trials loaded